# colorectal cancer - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 1
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 3704
- Completion tokens: 21046
- Reasoning tokens: 
- Total tokens: 24750
- API requests reported: 
- Elapsed seconds: 201.692
- Final benchmark system: raw; file rank 1/5; original repeat 1; model vendor: DeepSeek

---
I interpret the table as follows: **HR > 1 indicates higher expression associated with worse overall survival (risk-associated)**, and **HR < 1 indicates higher expression associated with better overall survival (protective-associated)**. I treat **FDR < 0.05** as the main statistical-support threshold; a few genes with FDR between 0.05 and 0.08 are mentioned only as suggestive. The input contains only prognostic HRs, not expression fold changes, so all statements about “higher” or “lower” expression refer to the HR direction for OS, not measured abundance changes.

## 1. Overall biological interpretation

The prognostic transcriptome separates colorectal cancer tumors into two broad biological states.

One state, associated with **worse OS**, is enriched for genes linked to **mesenchymal/EMT biology, TGF-β/activin signaling, cytoskeletal and invasive remodeling, glucose metabolism, and immune-evasion programs**. Representative genes include **INHBB, ZEB1-AS1, TPM4, DCBLD2, ITGBL1, ABL2, MAP1B, NIN, AKT3, NT5E, SLC2A3, and MIR31HG**. This pattern is broadly consistent with the poor-prognosis **CMS4/mesenchymal colorectal cancer subtype**.

The other state, associated with **better OS**, is enriched for genes linked to **intestinal epithelial differentiation and mitochondrial oxidative metabolism**. Representative genes include **CDX2, CDX1, MYO5B, LGALS4, PRR15L, NDUFA9, ATP5B, ATP5G1, CS, TIMM13, COA3, and OGDHL**. This pattern resembles a more differentiated, epithelial, intestinal-lineage phenotype, closer to CMS2/CMS3 biology.

These two patterns are not independent: loss of intestinal differentiation and gain of EMT/mesenchymal features often occur together in aggressive colorectal cancer. The table does not prove causation, but it supports a prognostic axis from **differentiated epithelial/mitochondrial tumors** toward **mesenchymal/EMT, growth-factor-driven tumors**.

---

## 2. Core biological programs

### Program 1: Loss of intestinal epithelial differentiation  
**Direction:** Protective-associated genes; HR < 1.

**Supporting genes:**  
- **CDX2** (HR 0.75, FDR 0.0355)  
- **CDX1** (HR 0.78, FDR 0.057, suggestive)  
- **MYO5B** (HR 0.75, FDR 0.028)  
- **LGALS4** (HR 0.77, FDR 0.051, suggestive)  
- **PRR15L** (HR 0.80, FDR 0.039)

**Appropriate pathway/ontology:** Closest standard terms include **GO:0030855 “epithelial cell differentiation”** and **GO:0060572 “morphogenesis of an epithelium”**. CDX2 and CDX1 are intestine-specific transcription factors, so a more specific intestinal-differentiation term would be ideal, but it is not consistently available in common pathway databases.

**Explanation:** CDX2/CDX1 are master regulators of intestinal identity. MYO5B is required for apical trafficking in differentiated intestinal epithelial cells; LGALS4 is an intestinal galectin enriched in differentiated epithelium. Higher expression of this intestinal-lineage program is associated with better survival, likely reflecting better-differentiated tumors with less aggressive behavior.

**Strength:** Supported by multiple independent genes with consistent protective direction and strong biological coherence.  
**Limitation:** This program overlaps with tumor grade and CMS subtype; CDX2-low tumors are known to have worse prognosis, so this may partly reflect subtype rather than an independent prognostic axis.

---

### Program 2: TGF-β/activin-driven EMT and cytoskeletal-invasive program  
**Direction:** Risk-associated genes; HR > 1.

**Supporting genes:**  
- **INHBB** (HR 1.43, FDR 0.0011)  
- **ZEB1-AS1** (HR 1.37, FDR 0.0086)  
- **DCBLD2** (HR 1.41, FDR 0.0086)  
- **TPM4** (HR 1.36, FDR 0.0089)  
- **ITGBL1** (HR 1.30, FDR 0.0306)  
- **ABL2** (HR 1.30, FDR 0.0276)  
- **MAP1B** (HR 1.33, FDR 0.0472)  
- **NIN** (HR 1.35, FDR 0.0282)

**Appropriate pathway/ontology:** **Hallmark “Epithelial Mesenchymal Transition”**; also Reactome **“Signaling by TGF-beta family members”**.

**Explanation:** INHBB encodes activin βB, a TGF-β-superfamily ligand. ZEB1-AS1 is an antisense RNA that can promote ZEB1, a master EMT transcription factor. TPM4, ABL2, MAP1B, and NIN are cytoskeletal/microtubule regulators that can support cell motility and invasion. ITGBL1 is associated with TGF-β signaling and stromal/mesenchymal biology in colorectal cancer. Together these genes point to an EMT/mesenchymal-invasive phenotype associated with worse OS.

**Strength:** Multiple genes from different EMT-related layers — signaling ligand, transcription-regulatory lncRNA, cytoskeletal effectors — converge on the same biological process.  
**Limitation:** Some genes, especially ITGBL1 and DCBLD2, may be expressed by cancer-associated fibroblasts or other stromal cells rather than by malignant epithelial cells in bulk tumor samples. This could reflect tumor microenvironment composition, not purely tumor-cell EMT.

---

### Program 3: Mitochondrial bioenergetics and oxidative phosphorylation  
**Direction:** Protective-associated genes; HR < 1.

**Supporting genes:**  
- **NDUFA9** (HR 0.69, FDR 0.0086)  
- **ATP23** (HR 0.69, FDR 0.0066)  
- **ATP5B** (HR 0.75, FDR 0.059, suggestive)  
- **ATP5G1** (HR 0.75, FDR 0.052, suggestive)  
- **CS** (HR 0.75, FDR 0.0388)  
- **TIMM13** (HR 0.75, FDR 0.0394)  
- **COA3** (HR 0.74, FDR 0.0434)  
- **OGDHL** (HR 0.69, FDR 0.074, suggestive)  
- **PRELID2** (HR 0.76, FDR 0.0404)

**Appropriate pathway/ontology:** **Hallmark “Oxidative Phosphorylation”**; Reactome **“The citric acid (TCA) cycle and respiratory electron transport”**.

**Explanation:** NDUFA9 is a Complex I subunit; ATP5B and ATP5G1 are ATP synthase components; CS is citrate synthase; TIMM13 and COA3 are mitochondrial import/assembly factors; OGDHL is a TCA-cycle-related gene. Higher expression of mitochondrial energy metabolism genes is associated with better OS. This could reflect a more differentiated, oxidative tumor phenotype or lower proliferative/glycolytic switch.

**Strength:** The signal is supported by many genes spanning multiple mitochondrial subsystems: Complex I, Complex V, TCA cycle, mitochondrial import, and complex assembly.  
**Limitation:** This pattern could be influenced by tumor purity, normal epithelial contamination, or proliferation state. Some mitochondrial genes are also highly expressed in non-malignant intestinal epithelium, so the association may reflect cellular composition rather than cancer-cell metabolism alone.

---

### Program 4: Antigen processing, apoptosis, and immune-visible tumor phenotype  
**Direction:** Protective-associated genes; HR < 1.

**Supporting genes:**  
- **TAPBPL** (HR 0.71, FDR 0.0192)  
- **LGALS9** (HR 0.75, FDR 0.042)  
- **BCL2L14** (HR 0.76, FDR 0.039)  
- **CASP6** (HR 0.77, FDR 0.045)

**Appropriate pathway/ontology:** KEGG **“Antigen processing and presentation”** for TAPBPL; KEGG **“Apoptosis”** for CASP6/BCL2L14.

**Explanation:** TAPBPL is related to the peptide-loading complex for MHC class I antigen presentation. BCL2L14 is a pro-apoptotic BCL-2 family member; CASP6 is an executioner caspase. LGALS9 encodes galectin-9, which can modulate T-cell responses and is often linked to immune regulation. Higher expression of these genes suggests tumors that are more apoptosis-competent and potentially more visible to the immune system, which may contribute to better survival.

**Strength:** The combination of antigen-presentation and apoptosis genes is biologically reasonable and supported by several independent protective genes.  
**Limitation:** LGALS9 has dual immunostimulatory and immunosuppressive roles depending on cellular context, so its interpretation is not unidirectional. This program is less well defined than the differentiation or mitochondrial programs.

---

### Program 5: PI3K/AKT, growth-factor signaling, glucose metabolism, and immune evasion  
**Direction:** Risk-associated genes; HR > 1.

**Supporting genes:**  
- **AKT3** (HR 1.32, FDR 0.0388)  
- **FGF19** (HR 1.29, FDR 0.051, suggestive)  
- **SLC2A3** (HR 1.28, FDR 0.072, suggestive)  
- **NT5E** (HR 1.31, FDR 0.039)  
- **MIR31HG** (HR 1.31, FDR 0.0066)  
- **GADD45B** (HR 1.32, FDR 0.063, suggestive)

**Appropriate pathway/ontology:** KEGG **“PI3K-Akt signaling pathway”**; Reactome **“Signaling by FGFR”**; Hallmark **“Glycolysis”** is partially relevant for SLC2A3.

**Explanation:** AKT3 is a direct PI3K/AKT effector. FGF19 is a growth-factor ligand that can signal through FGFR4 and is linked to colorectal cancer progression. SLC2A3 encodes GLUT3, a glucose transporter supporting glycolytic metabolism. NT5E encodes CD73, which generates immunosuppressive adenosine and can promote immune evasion. MIR31HG is an oncogenic lncRNA in colorectal cancer models. These genes collectively point to an aggressive phenotype driven by growth-factor signaling, metabolic reprogramming, and immune escape.

**Strength:** The biological direction is consistent and several genes are supported by strong literature in colorectal cancer.  
**Limitation:** This is the least homogeneous program; some genes have FDR above 0.05, and they do not necessarily belong to one single pathway. NT5E could also be part of a microenvironment/immune-evasion program rather than tumor-cell metabolism.

---

## 3. Key genes and interaction modules

### 1. CDX2  
**Direction:** Protective; HR 0.75, FDR 0.0355.  
**Role:** Master intestinal transcription factor; central to the intestinal differentiation program.  
**Gene-gene relationships:** CDX2 and CDX1 are co-expressed intestine-specific transcription factors with overlapping target genes; CDX2 may regulate CDX1 in some contexts. This is best described as **regulatory/pathway co-membership**, not direct physical interaction.

### 2. CDX1 / MYO5B / LGALS4 differentiation module  
**Direction:** Protective; CDX1 HR 0.78, MYO5B HR 0.75, LGALS4 HR 0.77.  
**Role:** CDX1 is the intestinal TF paralog; MYO5B supports apical vesicle trafficking; LGALS4 is an intestinal differentiation marker.  
**Gene-gene relationships:** These are **pathway co-members** of an intestinal epithelial differentiation network rather than confirmed direct protein interactors.

### 3. ZEB1-AS1  
**Direction:** Risk; HR 1.37, FDR 0.0086.  
**Role:** Antisense lncRNA to ZEB1; likely promotes EMT by upregulating ZEB1.  
**Gene-gene relationships:** ZEB1-AS1 is proposed to regulate ZEB1 expression via **regulatory interaction** (RNA/chromatin level); ZEB1 then regulates EMT target genes. There is no evidence of direct physical interaction at the protein level.

### 4. INHBB  
**Direction:** Risk; HR 1.43, FDR 0.0011.  
**Role:** Activin βB subunit; a TGF-β-superfamily ligand. It is the strongest risk-associated named gene in the table.  
**Gene-gene relationships:** INHBB is upstream of TGF-β/activin receptor signaling; its relationship to ZEB1-AS1/EMT genes is **pathway co-membership/indirect**, not direct binding.

### 5. TPM4 / ABL2 / MAP1B / NIN cytoskeletal module  
**Direction:** Risk; TPM4 HR 1.36, ABL2 HR 1.30, MAP1B HR 1.33, NIN HR 1.35.  
**Role:** Actin and microtubule regulators that may support invasion and migration.  
**Gene-gene relationships:** These genes are best considered **co-expressed functional pathway co-members** in cytoskeletal dynamics, not necessarily members of a single physical complex.

### 6. NDUFA9 / ATP5B / CS / COA3 / TIMM13 mitochondrial module  
**Direction:** Protective; HRs 0.69–0.75.  
**Role:** Subunits or assembly/import factors for oxidative phosphorylation and the TCA cycle.  
**Gene-gene relationships:** NDUFA9 and ATP5B are subunits of different OXPHOS complexes; CS is a TCA enzyme; COA3 and TIMM13 support mitochondrial protein assembly/import. This is **structural/pathway co-membership**, not direct interaction among all genes.

### 7. TAPBPL / LGALS9 / BCL2L14 / CASP6 immune-apoptosis module  
**Direction:** Protective; HRs 0.71–0.77.  
**Role:** Antigen-presentation machinery, immune modulation, and apoptosis competence.  
**Gene-gene relationships:** These are **pathway co-members** of immune-mediated tumor elimination and programmed cell death; no direct physical interaction among these four is established.

### 8. NT5E  
**Direction:** Risk; HR 1.31, FDR 0.039.  
**Role:** Encodes CD73, which produces adenosine and suppresses antitumor immunity.  
**Gene-gene relationships:** NT5E likely contributes to the immune-evasion phenotype through **indirect/putative** interactions with the tumor microenvironment. It is not directly validated as interacting with AKT3 or EMT genes from this dataset.

### 9. AKT3 / FGF19 signaling module  
**Direction:** Risk; AKT3 HR 1.32, FDR 0.0388; FGF19 HR 1.29, FDR 0.051, suggestive.  
**Role:** PI3K/AKT survival signaling and FGFR growth-factor signaling.  
**Gene-gene relationships:** AKT3 and FGF19 are **pathway co-members** of PI3K-AKT signaling; FGF19/FGFR4 can activate downstream AKT signaling. This is indirect/regulatory rather than direct physical interaction.

### 10. MIR31HG  
**Direction:** Risk; HR 1.31, FDR 0.0066.  
**Role:** Oncogenic long non-coding RNA implicated in colorectal cancer progression.  
**Gene-gene relationships:** MIR31HG is not currently assigned to a single validated pathway in this dataset; its relationship to the other risk genes is best described as **co-expression/indirect, with published literature suggesting oncogenic regulatory roles**.

---

## 4. Validation priorities

### 1. CDX2 / intestinal differentiation loss as a prognostic biomarker  
**Classification:** Biomarker  
**Why prioritized:** CDX2 is a strong protective gene, and CDX2 loss is already clinically recognized as a marker of aggressive colorectal cancer in some studies.  
**Current dataset evidence:** CDX2, CDX1, MYO5B, and LGALS4 are all protective-associated, supporting a coordinated differentiation-loss signal.  
**External evidence:** CDX2-low colorectal tumors are known to be more aggressive and frequently have poorer outcomes; CDX2 is a master intestinal transcription factor.  
**Next step:** Validate in an independent colorectal cancer cohort using CDX2 immunohistochemistry or RNA-seq, with adjustment for stage, MSI status, and CMS subtype.  
**Conclusion:** **Supported hypothesis** for the prognostic biomarker role; CDX2’s intestinal-differentiation function is established in developmental/gastrointestinal biology, but its prognostic utility in this specific dataset needs independent validation.

---

### 2. ZEB1-AS1 / ZEB1 EMT axis as a mechanistic driver of poor prognosis  
**Classification:** Mechanistic hypothesis  
**Why prioritized:** EMT is a major risk-associated program, and ZEB1-AS1 is one of the strongest risk lncRNAs in the dataset.  
**Current dataset evidence:** ZEB1-AS1 is risk-associated together with cytoskeletal/invasive genes TPM4, ABL2, and MAP1B.  
**External evidence:** ZEB1-AS1 has been reported to promote ZEB1 expression and EMT in several cancers, including colorectal cancer models.  
**Next step:** Use CRC organoids or cell lines with ZEB1-AS1 knockdown/overexpression to assess EMT markers, invasion, and metastasis in vivo.  
**Conclusion:** **Supported hypothesis**, but not established causal evidence from this dataset.

---

### 3. INHBB / activin / TGF-β signaling as a therapeutic target in high-risk CRC  
**Classification:** Therapeutic target  
**Why prioritized:** INHBB is the top risk-associated named gene, and TGF-β/activin signaling is a central upstream pathway linked to the EMT/mesenchymal phenotype.  
**Current dataset evidence:** INHBB is strongly risk-associated and aligns with the EMT/mesenchymal risk program.  
**External evidence:** TGF-β pathway activation is associated with CMS4 colorectal cancer and poor prognosis; however, TGF-β can also be tumor-suppressive in early-stage disease, so context matters. The existence of TGF-β inhibitors does not by itself prove efficacy in this setting.  
**Next step:** Test anti-activity/TGF-β pathway inhibition in patient-derived models selected for high INHBB and high EMT signatures, with careful staging and biomarker analysis.  
**Conclusion:** **Exploratory hypothesis** as a therapeutic target; the prognostic association is supported, but therapeutic causality is not established.

---

### 4. NT5E / CD73 adenosine pathway as a biomarker and immune-evasion target  
**Classification:** Therapeutic target / Biomarker  
**Why prioritized:** NT5E/CD73 is a targetable immune-evasion pathway in oncology, and NT5E is significantly risk-associated in this dataset.  
**Current dataset evidence:** NT5E HR 1.31, FDR 0.039, consistent with worse OS.  
**External evidence:** High CD73 expression has been associated with immunosuppression and poor outcomes in multiple tumor types, and anti-CD73 antibodies are in clinical development.  
**Next step:** Validate CD73 protein expression in CRC tissue, correlate with CD8+ T-cell infiltration and adenosine production, and test CD73 inhibition in immune-competent CRC models.  
**Conclusion:** **Supported hypothesis** for a prognostic/immune-evasion association; therapeutic efficacy remains exploratory.

---

### 5. Mitochondrial oxidative phosphorylation signal: true biology or composition artifact?  
**Classification:** Confounding or composition check  
**Why prioritized:** The protective OXPHOS signal is broad and biologically plausible, but mitochondrial genes can be highly sensitive to tumor purity, normal epithelial contamination, and stromal fraction.  
**Current dataset evidence:** Multiple independent mitochondrial genes are protective-associated, including NDUFA9, ATP5B, CS, TIMM13, and COA3.  
**External evidence:** Bulk tumor analyses often confuse cell-composition effects with cancer-cell-intrinsic metabolic programs.  
**Next step:** Use single-cell RNA-seq or digital cytometry to determine whether the mitochondrial expression is in malignant epithelial cells, normal epithelial cells, or tumor microenvironment cells; adjust for tumor purity and CMS subtype in survival models.  
**Conclusion:** **Exploratory hypothesis**; the protective association is present, but whether it reflects cancer-cell metabolism or tissue composition is unresolved.

---

## 5. Evidence grounding

The interpretations above are based on several evidence types:

- **Direct statistical evidence from the input dataset:** HR direction, P value, and FDR for each gene.
- **Pathway/ontology evidence:** Annotations from GO, Reactome, KEGG, and Hallmark gene sets based on known gene functions.
- **Published literature / disease-association evidence:** For example, CDX2 loss in aggressive CRC, EMT in CMS4, CD73 in immune evasion.
- **Expression/tissue-specific evidence:** CDX2/CDX1 are intestine-specific; mitochondrial genes are broadly expressed but high in differentiated intestinal epithelium; ITGBL1 may be stromal/mesenchymal.

These evidence sources are **not fully independent**. Pathway annotations and literature associations derive from the same accumulated biological knowledge. The input table is the only direct statistical dataset; external literature is used only to interpret biological plausibility. Where external evidence is conflicting — for example, LGALS9’s dual immune roles or TGF-β’s context-dependent behavior — I have explicitly noted the uncertainty.

---

## 6. Limitations and alternative explanations

### 1. Tumor purity and cell-composition differences  
Bulk colorectal tumor tissue contains epithelial cancer cells, normal epithelium, fibroblasts, endothelial cells, and immune cells. Genes such as **ITGBL1, DCBLD2, SCARA3, and NT5E** may be partly derived from stromal or immune cells rather than cancer cells. Protective genes such as **CDX2 and MYO5B** may partly reflect normal epithelial content.  
**How to investigate:** Use single-cell RNA-seq, spatial transcriptomics, multiplex IHC, and computational tumor-purity estimates to determine which cell types express these genes.

### 2. Disease stage, treatment exposure, and clinical confounders  
The table does not include stage, age, sex, MSI status, or treatment information. OS associations may reflect disease severity or treatment response rather than intrinsic biology.  
**How to investigate:** Adjust for stage and clinical covariates; validate in cohorts with detailed treatment and outcome annotation.

### 3. Platform/probe annotation ambiguity  
Several risk-associated features are unannotated probes or overlapping transcripts, such as **PROBE_237290_at**, **LOC101928747|RBMX|SNORD61**, and **MSANTD3-TMEFF1|TMEFF1**. These may represent technical artifacts, ambiguous mapping, or true but poorly annotated transcripts.  
**How to investigate:** Confirm with independent RNA-seq, RT-qPCR, or probe-specific validation.

### 4. Multiple testing and borderline FDRs  
The table contains many genes with FDR between 0.05 and 0.08. Some conclusions rely in part on suggestive genes. The risk of false positives is real, especially for single-gene interpretations.  
**How to investigate:** Use independent cohorts, gene-set-level analyses, and replication before treating individual genes as robust.

### 5. Association versus causation  
HRs from observational survival models cannot establish whether any gene drives prognosis. Even strong, biologically coherent associations may be markers of an underlying tumor subtype — for example, EMT-like CMS4 or differentiated CMS2 — rather than causal drivers.  
**How to investigate:** Functional perturbation experiments, genetically modified organoids, and randomized preclinical interventional designs are required before causal or therapeutic claims.

---

In summary, the current data support a coherent prognostic model in which **loss of intestinal differentiation and gain of TGF-β/EMT/mesenchymal-invasive features are associated with worse overall survival**, while **retention of intestinal differentiation and mitochondrial oxidative metabolism is associated with better overall survival**. The strongest individual candidates for further study are **CDX2-related differentiation loss, ZEB1-AS1-mediated EMT, INHBB/TGF-β signaling, and NT5E/CD73-mediated immune evasion**. These conclusions should be treated as biologically informed hypotheses, not as established causal mechanisms.
